These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32322207)

  • 1. Liraglutide Attenuates Non-Alcoholic Fatty Liver Disease in Mice by Regulating the Local Renin-Angiotensin System.
    Yang M; Ma X; Xuan X; Deng H; Chen Q; Yuan L
    Front Pharmacol; 2020; 11():432. PubMed ID: 32322207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renin-Angiotensin System in Liver Metabolism: Gender Differences and Role of Incretins.
    Mastoor Z; Diz-Chaves Y; González-Matías LC; Mallo F
    Metabolites; 2022 May; 12(5):. PubMed ID: 35629915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis activates Akt signaling to ameliorate hepatic steatosis.
    Cao X; Yang F; Shi T; Yuan M; Xin Z; Xie R; Li S; Li H; Yang JK
    Sci Rep; 2016 Feb; 6():21592. PubMed ID: 26883384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exercise training modulates the hepatic renin-angiotensin system in fructose-fed rats.
    Frantz EDC; Medeiros RF; Giori IG; Lima JBS; Bento-Bernardes T; Gaique TG; Fernandes-Santos C; Fernandes T; Oliveira EM; Vieira CP; Conte-Junior CA; Oliveira KJ; Nobrega ACL
    Exp Physiol; 2017 Sep; 102(9):1208-1220. PubMed ID: 28626963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of microRNA-124a attenuates non-alcoholic fatty liver disease through upregulation of adipose triglyceride lipase and the effect of liraglutide intervention.
    Fang QH; Shen QL; Li JJ; Yang Y; Guo JJ; Cheng Y; Zhou HC; Niu WY; Chen LM; Li CJ; Sun B
    Hepatol Res; 2019 Jul; 49(7):743-757. PubMed ID: 30861258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease.
    Gao H; Zeng Z; Zhang H; Zhou X; Guan L; Deng W; Xu L
    Biol Pharm Bull; 2015; 38(5):694-702. PubMed ID: 25947915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid disorder and intrahepatic renin-angiotensin system activation synergistically contribute to non-alcoholic fatty liver disease.
    Wu Y; Ma KL; Zhang Y; Wen Y; Wang GH; Hu ZB; Liu L; Lu J; Chen PP; Ruan XZ; Liu BC
    Liver Int; 2016 Oct; 36(10):1525-34. PubMed ID: 27028410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liraglutide protects against inflammatory stress in non-alcoholic fatty liver by modulating Kupffer cells M2 polarization via cAMP-PKA-STAT3 signaling pathway.
    Li Z; Feng PP; Zhao ZB; Zhu W; Gong JP; Du HM
    Biochem Biophys Res Commun; 2019 Feb; 510(1):20-26. PubMed ID: 30683312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liraglutide protects non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in a mouse model induced by high-fat diet.
    Zhu W; Feng PP; He K; Li SW; Gong JP
    Biochem Biophys Res Commun; 2018 Oct; 505(2):523-529. PubMed ID: 30269815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review.
    Borém LMA; Neto JFR; Brandi IV; Lelis DF; Santos SHS
    Hypertens Res; 2018 Jun; 41(6):394-405. PubMed ID: 29636553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin-converting enzyme 2 inhibits endoplasmic reticulum stress-associated pathway to preserve nonalcoholic fatty liver disease.
    Cao X; Song LN; Zhang YC; Li Q; Shi TT; Yang FY; Yuan MX; Xin Z; Yang JK
    Diabetes Metab Res Rev; 2019 May; 35(4):e3123. PubMed ID: 30604460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determining whether the effect of liraglutide on non-alcoholic fatty liver disease depends on reductions in the body mass index.
    Shiomi M; Tanaka Y; Takada T; Otori K
    JGH Open; 2020 Oct; 4(5):995-1001. PubMed ID: 33102775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resveratrol ameliorates maternal and post-weaning high-fat diet-induced nonalcoholic fatty liver disease via renin-angiotensin system.
    Tiao MM; Lin YJ; Yu HR; Sheen JM; Lin IC; Lai YJ; Tain YL; Huang LT; Tsai CC
    Lipids Health Dis; 2018 Jul; 17(1):178. PubMed ID: 30055626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway.
    Yang P; Liang Y; Luo Y; Li Z; Wen Y; Shen J; Li R; Zheng H; Gu HF; Xia N
    Diabetes Metab Syndr Obes; 2019; 12():1013-1021. PubMed ID: 31308717
    [No Abstract]   [Full Text] [Related]  

  • 15. Upregulation of angiotensin-converting enzyme (ACE) 2 in hepatic fibrosis by ACE inhibitors.
    Huang ML; Li X; Meng Y; Xiao B; Ma Q; Ying SS; Wu PS; Zhang ZS
    Clin Exp Pharmacol Physiol; 2010 Jan; 37(1):e1-6. PubMed ID: 19793108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK.
    Zhang L; Yang M; Ren H; Hu H; Boden G; Li L; Yang G
    Liver Int; 2013 May; 33(5):794-804. PubMed ID: 23432843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liraglutide Alleviates Hepatic Steatosis and Liver Injury in T2MD Rats via a GLP-1R Dependent AMPK Pathway.
    Zhou R; Lin C; Cheng Y; Zhuo X; Li Q; Xu W; Zhao L; Yang L
    Front Pharmacol; 2020; 11():600175. PubMed ID: 33746742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat.
    Lubel JS; Herath CB; Tchongue J; Grace J; Jia Z; Spencer K; Casley D; Crowley P; Sievert W; Burrell LM; Angus PW
    Clin Sci (Lond); 2009 Sep; 117(11):375-86. PubMed ID: 19371232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of renin-angiotensin system modulation on treatment and prevention of liver diseases.
    Moreira de Macêdo S; Guimarães TA; Feltenberger JD; Sousa Santos SH
    Peptides; 2014 Dec; 62():189-96. PubMed ID: 25453980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effects of the renin-angiotensin system blockers on nonalcoholic fatty liver disease and insulin resistance in C57BL/6 mice.
    Frantz ED; Penna-de-Carvalho A; Batista Tde M; Aguila MB; Mandarim-de-Lacerda CA
    Metab Syndr Relat Disord; 2014 May; 12(4):191-201. PubMed ID: 24517411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.